[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366435-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366435-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mechanistic-modeling-suggests-stroma-targeting-antibody-drug-conjugates-as-an-alternative-to-cancer-targeting-a-study-on-heterogeneous-target-expression","Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting - A study on heterogeneous target expression","","Antibody-drug conjugates (ADCs) show therapeutic promise for oncology, yet clinical failures occur. A central limitation is heterogeneous expression of the target antigen. While most ADCs target cancer cells, some can target stromal cells within the tumor microenvironment. The study builds three linked mathematical models to compare cancer-targeting with homogeneous versus heterogeneous antigen expression and stroma-targeting, using simulations to explain efficacy differences and bystander effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mechanistic-modeling-suggests-stroma-targeting-antibody-drug-conjugates-as-an-alternative-to-cancer-targeting-a-study-on-heterogeneous-target-expression/366435/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mechanistic-modeling-suggests-stroma-targeting-antibody-drug-conjugates-as-an-alternative-to-cancer-targeting-a-study-on-heterogeneous-target-expression/366435.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the paper address in ADC therapy?","Question",{"text":63,"@type":64},"ADC effectiveness is limited by heterogeneous expression of the target antigen. This heterogeneity can undermine cancer-targeting approaches and lead to regrowth after initial tumor shrinkage.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What models are introduced to study ADC behavior?",{"text":68,"@type":64},"The paper presents three related mathematical models: (1) cancer-targeting ADCs with homogeneous antigen expression, (2) cancer-targeting ADCs with heterogeneous antigen expression, and (3) stroma-targeting ADCs.",{"name":70,"@type":61,"acceptedAnswer":71},"How do stroma-targeting ADCs potentially improve outcomes in heterogeneous tumors?",{"text":72,"@type":64},"The simulations suggest stroma-targeting ADCs can overcome regrowth by continuing to recruit antigen-positive stromal cells into the tumor, driven by oncogenic factors from remaining cancer cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366435,1790630497,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","OPEN ACCESS  \nCitation: Wood NE, Cengiz A, Gao M, Ratushny AV, Straube R (2025) Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression. PLoS Comput Biol 21(8): e1012839. [https://](https://)[ ](https://)[doi.org/10.1371/journal.pcbi.1012839](doi.org/10.1371/journal.pcbi.1012839)  \nEditor: Marc R Birtwistle, Clemson University, UNITED STATES OF AMERICA  \nReceived: January 30, 2025  \nAccepted: July 23, 2025  \nPublished: August 13, 2025  \nCopyright: © 2025 Wood et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: All relevant data are within the manuscript and its Supporting  Information files.  \nFunding: NEW, AC, MG, AVR, and RS are funded by Bristol Myers Squibb. The fundershad no role in study design, data collection and  \nRESEARCH ARTICLE  \nMechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression  \nN. Ezgi Wood1*, Anıl Cengiz2, Ming Gao3, Alexander V. Ratushny4, Ronny Straube1¤  \n1 Quantitative Systems Pharmacology, Bristol Myers Squibb, Princeton, New Jersey, United States of America, 2 Department of Mathematics, University of Utah, Salt Lake City, Utah, United States of America, 3 Quantitative Systems Pharmacology, Bristol Myers Squibb, Cambridge, Massachusetts, United States of America, 4 Quantitative Systems Pharmacology, Bristol Myers Squibb, Seattle, Washington, United States of America  \n¤ Current address: Pioneering Medicines, Cambridge, Massachusetts, United States of America  \n* [nihal.wood@bms.com](nihal.wood@bms.com)  \nAbstract  \nAntibody-drug conjugates (ADCs) are gaining increasing traction in the treatment of oncological diseases; however, many clinical failures have also been observed. One key factor limiting ADC effectiveness is the heterogeneous expression of their target antigen. While the vast majority of ADCs in clinical development target antigens on cancer cells (cancer-targeting), they can also target antigens expressed on non-cancerous stromal cells in the tumor microenvironment (stroma-targeting) . It remains unclear if ADCs targeting stromal cells can outperform cancer-targeting ADCs. Here, we present three related mathematical models to evaluate: (1) cancertargeting ADCs with homogeneous target antigen expression,(2) cancer-targeting ADCs with heterogeneous target antigen expression, and (3) stroma-targeting ADCs. Our simulations suggest that cancer-targeting ADCs can achieve high efficacy when their target antigen is homogenously expressed. However, in cases of heterogeneous antigen expression, cancer-targeting ADCs may lead to an initial reduction in tumor size, followed by regrowth due to the elimination of antigen-positive cells and expansion of antigen-negative cells. This limitation could potentially be overcome by stroma-targeting ADCs, as antigen-positive stromal cells may continue to be recruited into the tumor by the oncogenic factors produced by the remaining cancer cells. Furthermore, we demonstrate that ADCs with more permeable payloads and less stable linkers may offer improved efficacy in the context of heterogeneous target expression.  \nPLOS Computational Biology | [https://doi.org/10.1371/journal.pcbi.1012839](https://doi.org/10.1371/journal.pcbi.1012839) August 13, 2025 1 / 16  \nanalysis, decision to publish, or preparation of the manuscript.  \nCompeting interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: NEW, MG, AVR are current BMS employees and own BMS stock. RS is a former BMS employee. AC was a BMS summer intern.  \nAuthor summary  \nAntibody-drug conjugates (ADCs) are targeted cancer therapies in whi","cbCaijktluhdJEVe","https://ap.wps.com/l/cbCaijktluhdJEVe","pdf",2495316,16,"English","# Abstract\n# Author Summary\n# Introduction\n## ADC components and mechanisms\n## Bystander killing in the tumor microenvironment","[{\"question\":\"What problem does the paper address in ADC therapy?\",\"answer\":\"ADC effectiveness is limited by heterogeneous expression of the target antigen. This heterogeneity can undermine cancer-targeting approaches and lead to regrowth after initial tumor shrinkage.\"},{\"question\":\"What models are introduced to study ADC behavior?\",\"answer\":\"The paper presents three related mathematical models: (1) cancer-targeting ADCs with homogeneous antigen expression, (2) cancer-targeting ADCs with heterogeneous antigen expression, and (3) stroma-targeting ADCs.\"},{\"question\":\"How do stroma-targeting ADCs potentially improve outcomes in heterogeneous tumors?\",\"answer\":\"The simulations suggest stroma-targeting ADCs can overcome regrowth by continuing to recruit antigen-positive stromal cells into the tumor, driven by oncogenic factors from remaining cancer cells.\"}]","Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting - A study on heterogeneous target expression | PDF",1790165542,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5edcc1093e1152ebae486004896cce06.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b990d0ad566c4472d7c1f1699e45e933.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5266cd411be5f02a090311322a697f8c.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30136e661248dcb927cb9193bcc5bcb4.webp",980,1268]